Direct compression cholestyramine tablet and solvent-free coating thereof

ABSTRACT

A directly compressed cholestyramine tablet with a solvent-free coating is disclosed. The inner core of the tablet is made up of cholestyramine agglomerates consisting of numerous small, irregularly-shaped, jagged-edged fragments having relatively few smooth or flat surfaces with a moisture content ranging from about 8 to 14 percent by weight. A process is also disclosed for preparing cholestyramine agglomerates of the invention. The solvent-free coating comprises from about 60 percent to about 95 percent by weight of stearic acid and from about 5 percent to about 40 percent of polyethylene glycol.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 07/764,115,filed Sep. 23, 1991, now abandoned, which is a continuation ofapplication Ser. No. 07/573,959, filed Aug. 27, 1990, now abandoned,which is a continuation-in-part of application Ser. No. 07/324,167,filed Mar. 16, 1989, now U.S. Pat. No. 4,956,182.

BACKGROUND OF THE INVENTION

Cholestyramine resin powder, which is the chloride salt of a basic anionexchange resin, is a cholesterol lowering agent intended for oraladministration. Although cholestyramine is quite hydrophilic, it isinsoluble in water and is not absorbed from the digestive tract.Cholestyramine is marketed by the Bristol-Myers Company as a powderunder the tradename QUESTRAN. The powder is not taken in its dry form,but is always mixed with water or other fluids before ingesting. Therecommended adult dose is four grams of cholestyramine resin from one tosix times daily. QUESTRAN is available as a powder in packets of ninegrams, four of which are relatively anhydrous cholestyramine resin. Theremaining five grams comprise other additives such as sucrose, flavoringand other ingredients to make the powder more palatable.

Obviously, it would be greatly desirable if cholestyramine resin couldbe put into tablet form, thereby eliminating the need for both mixingthe powder in water before ingesting, and adding additional materials torender the product palatable. It would be even more desirable if thecholestyramine resin could be rendered directly compressible into atablet, since direct compression is by far the desired tableting method,when compared to either wet or dry granulation methods. However, only avery limited number of pharmaceutical substances possess enough cohesivestrength and flowability to allow direct compression without previousgranulation. In fact, it is estimated that only about 20 percent of allmaterials used for tableting in the pharmaceutical field may be directlycompressed. In order to use this method to a greater extent, many morematerials are modified either by treating the material in some specialway during early stages of preparation, or by adding a directcompression vehicle that mixes with the active ingredient and forms aflowable and easily compressible mixture. It is, of course, desirable tobe able to directly compress a composition without addition of directcompression vehicles. Thus, it would be desirable to be able to directlycompress cholestyramine resin into a tablet, preferably without the aidof direct compression vehicles.

Even if one were to successfully directly compress cholestyramine into atablet, there is an additional problem that must still be overcome.Cholestyramine is extremely hygroscopic, which makes cholestyraminetablets very difficult to swallow. A cholestyramine tablet placed in themouth swells rapidly by readily taking up the available moisture. A verydry mouth results and the tablet adheres to the tongue, and thus cannotbe comfortably swallowed. Accordingly, it would be desirable to coat thetablet so as to render it easy to swallow.

Attempts to coat cholestyramine tablets, however, encounter difficultiesbecause coatings normally comprise either water or an organic solvent.It is impossible to coat cholestyramine tablets with a water-basedcoating because the hygroscopic tablets would swell during the coatingprocess. Although it is not difficult to coat cholestyramine with asolvent-based coating, cholestyramine has an affinity for the solventwhich is retained even after the drying processes. That is, thecholestyramine resin retains the solvent in the tablet matrix itself atlevels generally considered unacceptable. Such solvents often include analcohol (e.g., ethanol) and methylene chloride. While retained alcoholmight be acceptable, retained methylene chloride is not. Thus, there isa need for a coating which is neither water nor solvent based, and whichimparts swallowability to cholestyramine or other pharmaceuticaltablets.

U.S. Pat. No. 3,383,237 to Tuerck teaches a solvent-free coating appliedin a molten state at temperatures of 60° C. to 130° C. Tuerck teaches acoating composition comprising 60-90 percent by weight of polyethyleneglycol (PEG) with an average molecular weight of 1000-9000, and 10-40percent by weight of one or more synthetic or natural resins and gumswhich are miscible in a solution of PEG at temperatures of 45° C.-200°C. The application method described comprises tumbling tablets in arotating coating pan, preheating and maintaining the tablets at atemperature of 30° C. to 40° C., continuously applying the moltencomposition at temperatures of 60° C. to 130° C. onto the tablets untilthe desired coat thickness is obtained, and then tumbling/cooling thetablets to congeal the coating.

A second publication, Tuerck et al, Formula Modifications in aSolvent-Free Tablet Film Coat, J. Pharm. Sci., Vol. 62, 1534-37 (1973),describes the results of a screening study of 17 materials, includingstearic acid, used to modify a basic hot-melt composition containingeither 10 percent shellac and 90 percent PEG or 20 percent shellac and80 percent PEG. The materials were added individually to the two basichot-melt compositions at a level of 10 percent of the total composition.No other levels were evaluated. The modified compositions were thenapplied to tablets using the equipment and process described in theTuerck patent. Of the additives evaluated, Tuerck et al found that onlycastor oil, cocoa butter and isopropyl myristate improved the basicformulations.

Polyethylene glycol has a somewhat unpleasant burning taste. It has alsobeen found, that a high content of polyethylene glycol in tabletcoatings result in tablets that are rough looking or bumpy textured.Moreover, increasing the polyethylene glycol content past certainpercentages appears to decrease the durability of the coating asevidenced by cracking during handling. In general, PEG is not used intablet coating at high concentrations because of objectionable taste andodor. Thus, it would be desirable to formulate a solvent-free coatingthat eliminated the disadvantages resulting from high levels ofpolyethylene glycol.

Accordingly, it is an object of this invention to provide a process forproducing directly compressible cholestyramine tablets.

Another object of this invention is to provide agglomeratedcholestyramine particles that can be directly compressed into a tablethaving essentially no excipients or additives.

Yet another object of this invention is to provide a smooth,solvent-free coating that contains low amounts of polyethylene glycoland can be used to coat tablets such as cholestyramine.

SUMMARY OF THE INVENTION

Directly compressible cholestyramine agglomerated particles(agglomerates) are provided. The agglomerates are made up of numeroussmall, irregularly-shaped jagged-edged fragments having relatively fewsmooth or flat surfaces with a moisture content ranging from about 8percent to about 14 percent by weight. Pharmaceutical tabletspredominantly comprising the above-described cholestyramine agglomeratedparticles are also provided as well as a process for making the directlycompressible cholestyramine agglomerates.

A solvent-free coating is also provided, which coating comprises fromabout 60 percent to about 95 percent by weight of stearic acid, and fromabout 5 percent to about 40 percent by weight of polyethylene glycol.The solvent-free coating can be used to coat pharmaceutical tablets,including cholestyramine tablets prepared in accordance with thisinvention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1-4 are graphs showing the relationship between moisture content,compression force and average tablet hardness for cholestyramine tabletsprepared in accordance with this invention.

FIG. 5 is a graph showing the relationship between compression force andaverage tablet hardness for cholestyramine tablets prepared fromcholestyramine agglomerates (Z0620) in accordance with this inventionversus cholestyramine tablets prepared from cholestyramine powderedparticles (R1734) not in accordance with this invention.

FIG. 6 is a graph showing the relationship between compression force andaverage tablet hardness for directly compressed cholestyramine tabletsprepared from cholestyramine agglomerates Z0620 and AMBERLITEagglomerates obtained from DOWEX 1-X2 and AMBERLITE XE-268P beadlets,respectively, in accordance with this invention and AMBERLITE XE-268Ppowdered resin particles (R1734).

FIG. 7 is a scanning electron photomicrograph of DOWEX 1-X2cholestyramine beadlets that can be processed according to the instantinvention to provide cholestyramine agglomerates (FIG. 9) which can bedirectly compressed in accordance with this invention.

FIG. 8 is a scanning electron photomicrograph of AMBERLITE XE-268Pcholestyramine beadlets which can be processed according to the instantprocess of the invention to provide cholestyramine agglomerates (FIG.10) which can be directly compressed in accordance with this invention.

FIG. 9 is a scanning electron photomicrograph of cholestyramineagglomerates prepared from DOWEX 1-X2 cholestyramine resin beadlets thatcan be directly compressed into a tablet in accordance with thisinvention.

FIG. 10 is a scanning electron photomicrograph of cholestyramineagglomerates prepared from AMBERLITE XE-268P resin beadlets that can bedirectly compressed into a tablet in accordance with this invention.

FIG. 11 is a scanning electron photomicrograph of cholestyramineAMBERLITE XE-268P powdered resin particles, herein R1734, which cannotbe directly compressed.

DETAILED DESCRIPTION OF THE INVENTION

As discussed above, cholestyramine is extremely hygroscopic, andtherefore should be protected from contact with the mucous membrane ofthe mouth. Accordingly, tablets prepared in accordance with thisinvention comprise a direct compression cholestyramine "core tablet"encapsulated in a solvent-free coating such as the coating describedbelow.

The cholestyramine tablet inner core comprises directly compressedcholestyramine agglomerates, said agglomerates formed from smallirregularly-shaped, jagged-edged particles of cholestyramine withrelatively few large smooth or flat surfaces. Preferably, thecholestyramine agglomerates have a moisture content of 8-14%, a tappedbulk density of 0.45 to 0.5 g/ml, and when directly compressed providean inner core having a hardness of 18-26 SCU.

The solvent-free coating comprised of from about 60 to 90 percent byweight of stearic acid and from about 5 to 40 percent by weight ofpolyethylene glycol provides an easily swallowable tablet.

I. The Direct Compression Cholestyramine Core Tablet

It has been found that cholestyramine agglomerated particles of aparticular shape and water content are directly compressible intopharmaceutical tablets having acceptable hardness values. In particular,it has been found that cholestyramine particles are directlycompressible when they consist of agglomerated particles made up ofnumerous small, irregularly-shaped, jagged-edged fragments having few,if any, smooth or flat surfaces and a moisture content of from about8-14 percent by weight. The bulk density of the agglomerated particlesis from about 0.35-0.37 g/mL when loose, as determined by Sargent-WelchVolumeter apparatus, and from about 0.45-0.5 g/mL when tapped, asdetermined by a Tap-Pak Volumeter.

A process which can be used for producing the above-describedcholestyramine particles is as follows. Wet (approximately 70 percentwater) cholestyramine beadlets are hammer milled wet as is. Particularlypreferred cholestyramine beadlet raw material can be obtained from DowChemical Company under the trade name DOWEX 1-X2 Resin (herein DOWEXbeadlets). As shown in the FIG. 7 photomicrograph (300x), these beadletsare generally spherical in shape with a few beadlets having a partiallycollapsed surface. AMBERLITE XE-268P cholestyramine beadlets (hereinAMBERLITE beadlets) supplied by Rohm and Haas, Mozzanica, Italy, can beused but cholestyramine particles prepared therefrom according to theinstant process require appreciably greater compression forces toprovide durable tablets. As shown in the FIG. 8 photomicrograph (300x),AMBERLITE beadlets are also generally spherical in shape but aredistinguished from DOWEX beadlets (FIG. 7) in that the AMBERLITEbeadlets are fractured resulting in approximate beadlet half-sphereshaving relatively large, smooth, flat surfaces at the area of thefracture whereas DOWEX beadlets have no visable fractures with a fewbeadlets having partially collapsed surfaces. The beadlets are passedthrough a Mikro-Pulverizer either type 2-DH or 1SH from PulverizingMachinery, Summit N.J. The mill is equipped with 1/4" jump gap screenand six inlets open on the grinding chamber. Other types of conventionalmilling equipment are suitable with proper adjustment.

The hammer milled beadlet material is then dried to the desired moisturecontent of from about 8 percent to about 14 percent by weight,preferably from about 9 percent to about 13 percent by weight, and mostdesirably, from about 12-13 percent in a fluidized bed or other dryingequipment. When drying the milled material in a fluidized bed such as anAeromatic or Procedyne Drier the inlet temperature should be preferablyset at 48° C. to 58° C. and most preferably at 53° C. However, it ispossible to dry at temperatures outside the preferred range. Forinstance, temperatures in excess of 58° C. can be used at the start ofthe drying cycle but must be decreased to within the 48° C. to 58° C.range when the moisture content of the material approaches 8-14 percent.Failure to reduce the temperature will result in resin decompositionwith trimethylamine formation. Temperatures below 48° C. can be used butwill prolong the drying time and accordingly are not economicallyfeasible. During drying, the milled material has a tendency to formclumps and is sized to the desired cholestyramine agglomerated particlesize by using a Model D Fitzmill equipped with a #000 plate, impacthammers and set at high speed. Other mills conventionally used forsizing particles can also be employed.

Drying is critical to providing tablets of suitable durability. Forexample, as shown in FIG. 1, when the above-described milled materialhas a moisture content of about 9 percent, 3000 Kg of compressionresults in a tablet having a hardness of about 5 Strong Cobb Units(SCU). If the moisture content is increased to about 12.5 percent, thesame compression results in a tablet having a hardness of about 14 SCU.Increasing the pressure to 4000-6000 kg provides tablets having ahardness of about 18-22 SCU which is within the 18-26 SCU range desiredfor large-scale production. Increasing the moisture content above about12.5 percent yields little, if any, appreciable difference in hardnessat compression forces of 6000 Kg and above. Moisture contents of aboveabout 14 percent may result in lubrication problems during compression.

Conveniently, cholestyramine particles that have been dried to moisturecontents below the preferred ranges can simply be rewetted to within thepreferred ranges to provide compressibility similar to that of particleswhich have not been overdried as shown in FIGS. 2 and 4.

Adding a lubricant such as magnesium stearate is helpful in facilitatingejection of the tablets from the dies after compression and preventingsticking of the tablets to the punch faces. An amount of about 0.3percent by weight has provided acceptable results, with higher amountstending to provide diminished hardness values.

Optionally, other diluents can be added to the direct compressiblecholestyramine particles. However, such diluents are not necessarybecause a core tablet blend of cholestyramine having the above-describedmoisture contents is sufficiently compressible to provide acceptablecore tablets. Moreover, the presence of other diluents might have adetrimental effect on hardness, disintegration and/or stability. Otherdiluents include pregelatinized corn starch, lactose monohydrate,microcrystalline cellulose,

calcium phosphate, ungelatinized corn starch, and dextrose. The coretablet formulation can also contain disintegrants, which are substancesthat facilitate disintegration of the tablet in the presence of water orbiological fluids, and thus hasten the release of the activeingredients. The core tablet blend can also contain glidants, which arecompounds used to improve the flow of the core tablet blend and minimizetablet weight variation. Such additional ingredients will be readilyapparent to those skilled in the art and determining the optimum levelsof such ingredients is well within the ordinary skill of such personsusing routine experimentation.

As described above, the process for making cholestyramine agglomeratesfrom cholestyramine beadlets wherein said agglomerates can be directlycompressed into tablets comprises

(a) passing the wet beadlets through a hammer

mill micropulverizer to grind the beads;

(b) drying the ground beads at 48° C. to 58° C. to a moisture level of 8to 14 percent by weight;

(c) sizing the dried material to provide cholestyramine agglomerateswhich can be directly compressed into tablets, said agglomerates beingirregularly-shaped and jagged-edged with relatively few flat surfaces.

The cholestyramine agglomerates, together with any additionalingredients, are blended and tableted using conventional tableting meanswhich will be readily apparent to those skilled in the art.

II. The Solvent-Free Coating

As mentioned above, cholestyramine is hygroscopic and must therefore becoated to be swallowable. Unfortunately, conventional coating techniques(aqueous and organic solvents) cannot be used to coat cholestyraminebecause the resin has a high affinity for the solvents. Accordingly, anovel coating has been discovered that can be applied as a hot melt, andwhen cool, provides a wax-like coating that facilitates swallowing byslightly delaying tablet disintegration. The coating has a melting pointof approximately 55° C.-60° C.

The novel coating comprises from about 60-95 percent by weight ofstearic acid, and from about 5-40 percent by weight of polyethyleneglycol, which provides water miscibility. Preferably, the coatingcomprises 80-95 percent by weight of stearic acid and from 5-20 percentby weight of polyethylene glycol. Optionally, the coating can alsocontain from about 10-20 percent by weight of partially hydrogenatedvegetable oil such as soybean, cottonseed, etc. The addition of thelatter ingredient provides a coated tablet having better defined shapeand edges. A suitable partially hydrogenated soybean oil is availablefrom Durkee Foods under the tradename DURKEE 17. A particularly goodcoating comprises about 80 percent stearic acid, about 15 percentpartially hydrogenated soybean oil, and about 5 percent polyethyleneglycol.

The coating can, of course, contain other additives such as coloring,flavoring and processing agents. Such additives will be readily apparentto those skilled in the art.

The general process for applying the coating is described in Tuerck,U.S. Pat. 3,383,237, incorporated herein by reference, and consists ofmelting and mixing the coating ingredients, preheating the tablets, andapplying the melted coating using a spray apparatus until sufficientcoat is applied to provide the desired tablet disintegration time.Generally a coating of approximately 50-150 mg per gram tablet issatisfactory with an average coat weight of 80-100 mg preferred. Thebasic equipment for this process comprises a coating pan (preferablybaffled) with a source for heated process air, a heated apparatus formelting and pumping/recirculating the coating materials, and a sprayingsystem utilizing heated atomizing air to apply the coating materials.

Examples 1 and 2 illustrate the dramatic effect of moisture content onthe compressibility of cholestyramine agglomerates in accordance withthis invention.

EXAMPLE 1 Effect of Moisture on Tablets Prepared From CholestyramineAgglomerates Obtained by Wet Milling DOWEX Beadlets

An experiment was conducted to determine the influence of moisturecontent on the compression characteristics of cholestyramineagglomerates in accordance with this invention. Ground, driedcholestyramine was prepared from DOWEX beadlets as described above. Themoisture content was 8.8 percent as determined by loss on drying (16hours, 70° C., vacuum oven). A portion of the material was held as is.The moisture content of other portions was altered to achieve targetmoisture contents of about 5.0 percent, 7.5 percent, 12.0 percent, or15.0 percent. This was accomplished by drying the material in a forcedair oven (22 hours at 53° C. then 8 hours at 65° C.) or by drying in avacuum oven at 70° C. for 5.5 hours or by adding calculated amounts ofwater. When water was added, the material was blended for 5 minutes in a0.67 cubic foot Lodige mixer at 210 rpm with the chopper off. The wettedmaterial was then hand screened through a 30 mesh screen and blended foran additional 5 minutes. In addition, the moisture content of the vacuumdried material was brought back to the original moisture content byadding a calculated amount of water and blending as previouslydescribed. All samples were held in a closed glass container for atleast 24 hours prior to use.

Tablet blends were prepared by mixing a common blend of inactiveexcipients with each portion of cholestyramine in the Lodige mixer for 5minutes at 210 rpm with the choppers off. The blends were compressed onan instrumented Manestry D3B tablet press at different compressionforces using 0.835" x 0.360" capsule shaped tooling. The compressionforces used to make tablets were recorded. The hardness of resultingtablets were measured with a Pharmatest Hardness Tester (Model HT-300).

Results and Discussion

Compression profiles comparing compression force and resulting tablethardness for each tablet blend are illustrated in FIG. 1. These resultsclearly demonstrate that cholestyramine moisture content affects thecompressibility of the tablet blend, i.e., as the moisture contentincreased, harder tablets could be produced and less compression forcewas required to achieve comparable tablet hardnesses. This effectdiminished, however, when the moisture content exceeded 12.6 percent andno remarkable difference was obvious between blends containingcholestyramine 12.6 percent or 14.1 percent moisture contents.

The only tableting problem occurred when compressing the blendcontaining cholestyramine with the highest moisture content (14.1percent). This blend caused the tablet tooling to bind in the dies. Themagnesium stearate concentration was increased to 7 mg per tablet, whicheliminated munch binding but adversely affected compression. The highesthardness attainable was 10.5 SCU.

When the moisture content of the driest cholestyramine portion (5.2percent) was restored to near its original moisture content (9.9percent), the resulting blend had a compression profile nearly the sameas the blend made with the original cholestyramine. This phenomenon isillustrated in FIG. 2 and indicates that overdried batches ofcholestyramine can be rendered compressible by adding appropriateamounts of water. Trimethylamine (TMA) odor was detected from theoverdried cholestyramine (5.2 percent). The TMA content for the 5.2percent material was 41 ppm and 17 ppm for the original material. Thus,overdrying of cholestyramine will result in higher TMA concentrations.

In conclusion, this example illustrates how the moisture content ofcholestyramine agglomerates in accordance with this invention influencesthe compression characteristics of tablets made therefrom. Thecompression characteristics of tablet blends will improve as themoisture content is increased up to approximately 12.6 percent. Overlydried batches of cholestyramine can be salvaged, in terms ofcompressibility, by adding appropriate amounts of water.

EXAMPLE 2 Effect on Tablet Hardness of Adding Moisture To Overly DriedCholestyramine Agglomerates Obtained by Wet Milling DOWEX Beadlets

Example 1 was repeated using a different batch of DOWEX beadlets todetermine reproducibility of the results. The moisture content was 9.1percent as determined by loss on drying (16 hours, 70° C., vacuum oven).A portion of the material was held as is. The moisture content of otherportions was altered to achieve target moisture contents of about 5.0percent, 7.5 percent, 12.0 percent, or 15.0 percent. This wasaccomplished by drying the material in a vacuum oven at 70° C. foreither 2.5 hours or 5.5 hours or by adding calculated amounts of water.When water was added, the material was blended for 5 minutes in a 0.67cubic foot Lodige mixer at 210 rpm with the chopper off. The wettedmaterial was then hand screened through a 30 mesh screen and blended foran additional 5 minutes. In addition, the moisture content of the vacuumdried material was brought back to near its original moisture content byadding a calculated amount of water and blending as previouslydescribed. All samples were held in a closed glass container for atleast 24 hours prior to use.

Tablet blends were prepared by mixing a common blend of inactiveexcipients with each portion of cholestyramine in the Lodige mixer for 5minutes at 210 rpm with the choppers off. The blends were compressed onan instrumented Manesty D3B tablet Dress at different compression forcesusing 0.835 inch x 0.360 inch capsule shaped tooling. The compressionforces used to make tablets were recorded. The hardness of resultingtablets was measured with a Pharmatest Hardness Tester (Model HT-300).

Results and Discussion

Compression profiles comparing compression force and resulting tablethardness for each tablet blend are illustrated in FIG. 3. The profileswere similar to those from Example 1 (FIG. 1) and clearly demonstratethat cholestyramine moisture content affects the compressibility ofcholestyramine agglomerates in accordance with this invention, i.e., asthe moisture content increased, harder tablets could be produced andless compression force was required to achieve comparable tablethardnesses. This effect diminished, however, when the moisture contentexceeded 12.0 percent and no remarkable difference was obvious betweenthe blends containing cholestyramine with 12.0 percent or 14.9 percentmoisture contents.

The only tableting problem occurred when compressing the blendcontaining cholestyramine with the highest moisture content (14.9percent). This blend caused the tablet tooling to bind in the dies. Themagnesium stearate content was increased up to 6 mg per tablet, but didnot eliminate punch binding. Moreover, compression was adverselyaffected by increasing the magnesium stearate, i.e., the highesthardness attainable was 12.5 SCU. Results from Example 1 indicated that7 rag per tablet eliminated punch binding but compression was affectedto a greater degree. That is, only a hardness of 10.5 SCU wasattainable.

When the moisture content of the driest cholestyramine portion (5.8percent) was restored to near its original moisture content (8.8percent), the resulting blend has a compression profile nearly the sameas the blend made with the original cholestyramine. The profiles areillustrated in FIG. 4 and are in agreement with Example 1 (FIG. 2) whichindicates that overdried batches of cholestyramine can be renderedcompressible by adding appropriate amounts of water. TMA odor was againdetected from the overdried cholestyramine (5.8 percent). The TMAcontent for the 5.8 percent material was 48 ppm and 10 ppm for theoriginal material. Thus, as observed in Example 1, over-drying ofcholestyramine will result in higher TMA concentrations.

In conclusion Example 2 illustrates that the moisture content of theground, dried cholestyramine particles in accordance with this inventioninfluences the compression characteristics of tablets made therefrom.The compression characteristics of tablet blends will improve as themoisture content is increased up to approximately 12.0 percent. Overlydried batches of cholestyramine can be salvaged, in terms ofcompressibility, by adding appropriate amounts of water. The results ofthis study are comparable to the results from Example 1.

Examples 3 , 4 , and 5 illustrate that cholestyramine agglomerates inaccordance with this invention are directly compressible, and thatcholestyramine particles that are not in accordance with the inventiondo not have similar properties.

In these examples, AMBERLITE powdered resin was compared withcholestyramine agglomerates obtained according to the instant process.As shown in TABLE I below, the particle size of the of the DOWEXagglomerates (Z0620), AMBERLITE agglomerates and AMBERLITE powderedresin (R1734) are approximately the same.

                  TABLE I                                                         ______________________________________                                        PARTICLE SIZE DISTRIBUTION                                                    (Alpine Sieve Apparatus)                                                              Percent Retained                                                                            AMBERLITE                                               Mesh Size Z0620       Agglomerates                                                                              R1734                                       ______________________________________                                         60        5           0           0                                           80        2           6           0                                          100        6           2           3                                          200       37          36          30                                          325       33          46          34                                          Thru 325  17          10          33                                          ______________________________________                                    

However, scanning electron photomicrographs (250x) (FIGS. 9, 10, and 11)of the agglomerates and R1734 powdered resin taken at a magnification of250X indicate significant differences in appearance of the particles. Asillustrated by FIG. 9, the overall size of the Z0620 particles issimilar to or slightly larger than the AMBERLITE agglomerates or R1734powdered resin. FIG. 10 illustrates that AMBERLITE agglomerates consistof small particles attached to a larger core particle. As seen in FIG.11, the R1734 powder has a predominance of large single particles withvery little agglomerated material. Differences in shape are also shownin the photomicrographs. The Z0620 particles (FIG. 9) are irregular inshape, as are particles from the other two powders. However, the Z0620particles have jagged edges and relatively few large smooth/flatsurfaces. The AMBERLITE particles (FIG. 10) are more like the Z0620agglomerates than the R1734 powdered resin but show evidence of someparticles having smooth/flat surfaces. The R1734 powder (FIG. 11)predominantly consists of particles having relatively large, smooth/flatsurfaces. It is evident, therefore, that particles suitable for directcompression should consist of agglomerates formed from many small,irregularly-shaped, jagged-edged particles. These particles are morecohesive and thus have the propensity to agglomerate and easily bondduring compression, to produce durable tablets at low compressionforces.

The bulk density of the DOWEX and AMBERLITE agglomerates and AMBERLITEpowdered resin was determined for comparison purposes. Typical resultsin TABLE II below show that the Z0620 is the least dense, followed bythe AMBERLITE agglomerates and finally the R1734 powder which has thehighest (tapped) density.

                  TABLE II                                                        ______________________________________                                        BULK DENSITY                                                                                    Density (g/mL)                                              Powder              Loose*  Tapped**                                          ______________________________________                                        Z0620               0.363   0.478                                             AMBERLITE agglomerates                                                                            0.370   0.485                                             R1734               0.382   0.525                                             ______________________________________                                         *Sargent Welch Volumeter                                                      **TapPak Volumeter                                                       

Thus, the cholestyramine agglomerates suitable for direct compressionhave a loose bulk density of 0.35 to 0.37 g/mL and a tapped bulk densityof 0.45 to 0.5 g/mL with a preferred tapped bulk density of 0.47 to 0.49g/mL.

EXAMPLE 3 Compressibility Comparison of AMBERLITE R1734 Powdered Resinand Cholestyramine Agglomerates of this Invention

Two different lots of AMBERLITE R1734 powdered resin were used toprepare two batches of 1 g cholestyramine tablets. The first lotcontained about 9.2 percent by weight moisture and the second lotcontained about 8.4 percent by weight moisture. The highest attainablehardness for the tablet batches were 7.0 SCU and 7.5 SCU, and thetablets produced were not durable because they failed a friability testof 100 drops. In contrast, when particles in accordance with thisinvention were used in nearly identical compositions, a tablet hardnessof 21 SCU could be achieved. Tablets compressed within the in-processrange of 18 SCU to 26 SCU passed the friability test.

Another lot of AMBERLITE R1734 powdered resin having an average moisturecontent of 9.0 percent by weight water was used in an unsuccessfulattempt to manufacture 1 g cholestyramine core tablets. The highestattainable tablet hardness at compression force of about 7 to 9kilograms was only 10 SCU and the tablets were not durable. In contrast,several batches of core tablets were successfully produced withcholestyramine agglomerates according to this invention having moisturecontents ranging from 7.6 percent to 10.5 percent by weight. The tabletswere compressed to 22 SCU (considered optimum hardness) and weresufficiently durable to pass the friability test and withstand a coatingprocess.

This study demonstrates that selection of cholestyramine agglomeratesaccording to the instant invention is critical to providing directlycompressed tablets of suitable hardness.

EXAMPLE 4 Compressibility Comparison of the Effect of Moisture onTablets Prepared From AMBERLITE R1734 Powdered Resin and CholestyramineParticles of this Invention

An experiment was performed to compare the compression properties oftablets prepared from cholestyramine agglomerates of this inventionhaving 12.5 percent by weight moisture with 3 lots of the AMBERLITER1734 powdered resin having 10 percent, 12.5 percent and 15 percent byweight moisture. Results are shown in FIG. 5.

This study demonstrates that compression characteristics of theAMBERLITE R1734 powdered resin are unacceptable regardless of moisturecontent. The highest attainable tablet hardness of 12-13 SCU wasachieved only by using excessive compression force. In contrast,directly compressed tablets manufactured with cholestyramineagglomerates (herein designated DOWEX Z0620) obtained from DOWEXbeadlets according to this invention easily met the compression criteriaof 18 to 26 SCU, and in fact could be compressed to hardness valuesexceeding 18 SCU without excessive compression force.

EXAMPLE 5 Compressibility Comparison of Cholestyramine AgglomeratesObtained From DOWEX and AMBERLITE Beadlets According to this Inventionand AMBERLITE R1734 Powdered Resin

An experiment was performed to compare compression properties ofcholestyramine agglomerates of this invention with AMBERLITE powderedresin (R1734). The cholestyramine agglomerates and AMBERLITE R1734powdered resin had a moisture content of 9-10 percent.

For purposes of large-scale manufacturing, tablets must have SCU averagehardness values of 18 to 26, preferably 20 to 24 and most preferably 22to 23 to withstand handling during coating and packing.

FIG. 6 sets out the results of the study, and it is evident that in theacceptable hardness range, only the DOWEX agglomerates (Z0620) andAMBERLITE agglomerates obtained according to the instant process can bedirectly compressed to provide tablets having the desired hardness. FIG.6 also illustrates that DOWEX beadlets are preferred over AMBERLITEbeadlets as raw material in that relatively harder tablets are obtainedwith DOWEX particles.

This comparative study clearly demonstrates that direct compressedtablets made with AMBERLITE R1734 powdered resin are distinctiveinferior with respect to tablet hardness and durability compared totablets made from cholestyramine agglomerates of the instant invention.

EXAMPLE 6 Preparation of Directly Compressed, Coated Cholestyramine 1.0gram Tablets

Tablets were prepared by compressing a mixture of cholestyramine (99.7%)and magnesium stearate (0.3%) into 0.360 inch x 0.835 inchcapsule-shaped tablets, weighing approximately 1120 mg each.

The molten coating composition, consisting of stearic acid (80%),partially hydrogenated soybean oil (15%), and 5% polyethylene glycol3350 (molecular weight range 3015-3685), was prepared by combining thecomponents in a container and heating them to a temperature of 90° -100°C., while stirring, to form a uniform molten mixture.

Approximately 6000 tablets (6.7 kg) were placed in a 24-inch Accela-Cotapan and warmed to a temperature of 40° -45° C. by introducing heated airinto the pan. The heated tablets were then tumbled in the pan (rotatingat 10 rpm), and with the heated air to the pan continuing, were coatedwith the molten coating material. The apparatus used to apply the coatto the tablets consisted of a heated pump/transfer line system connectedto a 4-nozzle pneumatic spray system. Heated air at 110° -120° C. wassupplied to the spray system to heat the nozzles and atomize the moltencoating material. The coat application continued until a coat weighingapproximately 130 mg/tablet was coated. This application required 40-45minutes to complete. The coated tablets were then allowed to tumble andcool for about 10 minutes.

What is claimed is:
 1. A cholestyramine tablet inner core consisting ofdirectly compressed cholestyramine agglomerates and about 0.3 percent byweight of a lubricant, said agglomerates having a moisture content of 8to 14 percent and formed from many small irregularly-shaped, jagged-edgeparticles with relatively few large smooth or flat surfaces wherein saidagglomerates, when directly compressed, provide an inner core having ahardness of at least 18 SCU.
 2. A cholestyramine tablet inner core ofclaim 1 wherein said agglomerates have a tapped bulk density of 0.45 to0.5 g/ml.
 3. A cholestyramine tablet inner core of claim 1 wherein saidagglomerates, when directly compressed, provide an inner core having ahardness of 18 to 26 SCU.
 4. A cholestyramine tablet inner core of claim1 wherein said lubricant is magnesium stearate.
 5. A cholestyraminetablet inner core consisting of directly compressed cholestyramineagglomerates and about 0.3 percent by weight of magnesium stearate, saidagglomerates having a tapped bulk density of 0.45 to 0.5 g/ml and amoisture content of 8 to 14 percent and formed from many smallirregularly-shaped, jagged-edge particles with relatively few largesmooth or flat surfaces wherein said agglomerates, when directlycompressed, provide an inner core having a hardness of 18 to 26 SCU.